In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
1. Why, When, and How to Use Pre-Exposure
Prophylaxis (PrEP) for HIV Acquisition:
Guidance for Midlevel Practitioners
Marcy S. Gelman, RN, MSN, MPH
Director of Operations and Clinical
Research
The Fenway Institute
Fenway Community Health
Boston, Massachusetts
Kevin M. O’Hara, PA
Assistant Professor of Medicine
Physician Associate Program
Yale School of Medicine
New Haven, Connecticut
This activity is supported by an independent educational grant
from Gilead Sciences.
2. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
About These Slides
Users are encouraged to use these slides in their own
noncommercial presentations, but we ask that content
and attribution not be changed. Users are asked to honor
this intent
These slides may not be published or posted online
without permission from Clinical Care Options
(email permissions@clinicaloptions.com)
Disclaimer
The materials published on the Clinical Care Options Web site reflect the views of the authors of the
CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing
educational grants. The materials may discuss uses and dosages for therapeutic products that have not
been approved by the United States Food and Drug Administration. A qualified healthcare professional
should be consulted before using any therapeutic product discussed. Readers should verify all information
and data before treating patients or using any therapies described in these materials.
3. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Faculty
Marcy S. Gelman, RN,
MSN, MPH
Director of Operations and
Clinical Research
The Fenway Institute
Fenway Community Health
Boston, Massachusetts
Kevin M. O’Hara, PA
Assistant Professor of Medicine
Physician Associate Program
Yale School of Medicine
New Haven, Connecticut
4. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Faculty Disclosures
Marcy S. Gelman, RN, MSN, MPH, has no significant
financial relationships to disclose.
Kevin M. O’Hara, PA, has disclosed that he has ownership
interest in AbbVie and Gilead Sciences.
6. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
HIV/AIDS in the United States and
Worldwide
Approximately 1.1 million people are living with HIV/AIDS in the
United States
– An estimated 1 in 6 (15.8%) of those people are undiagnosed
– Since the start of the epidemic, 636,000 people have died of AIDS
– An estimated 50,000 new HIV infections occur in the US every yr
More than 35 million people are living with HIV/AIDS worldwide,
of whom 3.3 million are younger than 15 yrs of age
– In 2012, an estimated 2.3 million people were newly infected with
HIV
CDC. HIV Surveillance Report. 2013;18(no.5). CDC. HIV Surveillance Report, 2011; vol. 23.
UNAIDS Report On the Global AIDS Epidemic 2013.
7. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
The Need for HIV Prevention: Continued
HIV Risk in the US
Estimated new HIV infections in the United States for the
most affected subpopulations, 2008-2011
2008 2009 2010 2011
70
60
50
40
30
CDC. HIV in the United States: 2013.
Yr
0
Diagnoses (%)
20
10
Male-to-male sexual contact
Heterosexual contact
IDU
Male-to-male sexual
contact and IDU
Other
8. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
HIV Prevention: Toolbox for Success
Safer-sex counseling: understanding risk
Condoms and lubricant
Sterile syringes and avoiding sharing “works”
HIV testing
STI testing and treatment
PEP (postexposure prophylaxis)
PrEP (pre-exposure prophylaxis)
9. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
What Is PrEP?
For PrEP, an HIV-uninfected individual takes antiretroviral
medication(s) before potential HIV exposure
The idea of providing a medication as prophylaxis against
an infectious disease is well established, eg:
– Use of antimalarials before traveling to malarial zones
– Use of antibiotics prior to dental procedures
Oral contraceptives are also used prophylactically to
prevent pregnancy
10. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Antiretrovirals Used in HIV Prevention:
The Foundation for PrEP
Prevention of mother-to-child transmission
– Antiretrovirals given to the mother during pregnancy, labor,
and delivery and to the infant postpartum[1]
– PMTCT has virtually eliminated perinatal HIV infection in the
US and other developed countries
Postexposure prophylaxis
– Antiretrovirals given within hrs of a known or suspected HIV
exposure (eg, needle stick injury, rape)
– US public health guidance for PEP is available for both
occupational[2] and nonoccupational[3] exposure to HIV
1. DHHS. Perinatal Guidelines. 2014. 2. Kuhar DT, et al. Infect Control Hosp Epidemiol. 2013;34:875-892.
3. MMWR. 2005;54(RR-2):1-20.
11. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Pre- vs Postexposure Prophylaxis
After exposure to HIV,
infection may become
established
Postexposure prophylaxis
(initiated soon after
exposure) reduces the
chance of infection
Pre-exposure prophylaxis
begins treatment earlier
(before exposure), which
might increase the
prophylactic effect
HIV
infection
HIV
exposure
0 hr 36 hrs 72 hrs
1 mos 3 mos 5 mos
Postexposure
prophylaxis
Pre-exposure
prophylaxis
12. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
PrEP Trials Have Shown Efficacy in MSM,
Heterosexual Men and Women, and IDUs
Trial Population/Setting Intervention HIV Infections, n Reduction in
HIV Infection Rate,
PrEP Placebo % (95% CI)
iPrEX[1]
(N = 2499)
MSM, transgender women,
11 sites in US, South
America, Africa, Thailand
TDF/FTC 36 64 44 (15-63)
Partners
PrEP[2]
(N = 4747)
Serodiscordant couples
in Africa
TDF 17
52
67 (44-81)
TDF/FTC 13 75 (55-87)
TDF2[3]
(N = 1219)
Heterosexual males and
females in Botswana TDF/FTC 9 24 62 (21-83)
Thai IDU[4]
(N = 2413)
Volunteers from 17 drug
Thai treatment centers TDF 17 33 49 (10-72)
2 additional trials of PrEP (FEM-PrEP[5] and VOICE[6]), both conducted among high-risk African
women, did not demonstrate protection against HIV; in both trials, PrEP adherence was very low
1. Grant RM, et al. N Engl J Med. 2010;363:2587-2599. 2. Baeten JM, et al. N Engl J Med. 2012;367:399-
410. 3. Thigpen MC, et al. N Engl J Med. 2012;367:423-434. 4. Choopanya K, et al. Lancet. 2013;381:2083-
2090. 5. Van Damme L, et al. N Engl J Med. 2012;367:411-422. 6. Marrazzo J, et al. CROI 2013. Abstract
26LB.
13. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
PrEP Works, but Adherence Is Critical
Study Efficacy
Overall, %
Blood Samples With
TFV Detected, %
Efficacy By Blood
Detection of TFV, %
iPrEx[1] 44 51 92
iPrEx OLE[2] 49 71 NR
Partners
PrEP[3]
67 (TDF)
75 (TDF/FTC) 81 86 (TDF)
90 (TDF/FTC)
TDF2[4] 62 80 85
Thai IDU[5] 49 67 74
Fem-PrEP[6] No efficacy < 30 NR
VOICE[7] No efficacy < 30 NR
1. Grant RM, et al. N Engl J Med. 2010;363:2587-2599. 2. Grant RM, et al. Lancet Infect Dis. 2014;
14:820-829. 3. Baeten JM, et al. N Engl J Med. 2012;367:399-410. 4. Thigpen MC, et al. N Engl J Med.
2012;367:423-434. 5. Choopanya K, et al. Lancet. 2013;381:2083-2090. 6. Van Damme L, et al. N Engl
J Med. 2012;367:411-422. 7. Marrazzo J, et al. CROI 2013. Abstract 26LB.
14. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
PrEP in Clinical Practice: What Are the
Barriers to PrEP Uptake?
Users
– Unaware of HIV risk,
PrEP availability, or how
to access it
– No or delayed access to
clinical preventive care
– Uninsured or unable to
pay
– Adherence challenges
– Concern about disclosure
and stigma
Providers
– Unaware of intervention
– Uncertain how to deliver
the intervention
– Wary of complexity and
time involved
– Discomfort with
assessing candidacy
– Uncertain how to bill for
intervention
16. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Provider–Patient Decision Making
The role of the provider is to help the patient:
– Understand the likely outcomes of various options
– Think about what is personally important about the risks and
benefits of each option
– Participate in decisions
These decisions are difficult because:
– There may be more than 1 choice
– Each choice has advantages and disadvantages
– There is no “correct” choice; what you choose depends on
what is important to you
17. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
CDC PrEP Guideline: For Which Patients
Is PrEP Recommended?
PrEP is recommended as one prevention option for the following
adults at substantial risk of HIV acquisition
– Sexually active MSM
– Heterosexually active men and women
– Injection drug users
MSM Heterosexual Women and Men Injection Drug Users
Potential
indicators of
substantial
risk of
acquiring HIV
infection
HIV-positive sexual
partner
Recent bacterial STI
High number of sex
partners
History of inconsistent
or no condom use
Commercial sex work
HIV-positive sexual partner
Recent bacterial STI
High number of sex partners
History of inconsistent or no
condom use
Commercial sex work
In high-prevalence area or
network
HIV-positive injecting
partner
Sharing injection
equipment
Recent drug
treatment (but
currently injecting)
CDC. PrEP Guideline. 2014.
18. “Ironically, it may require
greater intimacy to discuss sex
than to engage in it”
The Hidden Epidemic
Institute of Medicine, 1997
19. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Many Patients Want Clinicians to Ask
About Sexual Issues
In a survey of adults, 85% expressed an interest in talking
to their providers about sexual issues; 71% thought their
provider would likely dismiss their concerns[1]
In a survey of PCPs, 94% routinely asked patients about
smoking, whereas 49% asked about STIs, and 27% about
sexual orientation[2]
1. Marwick C. JAMA 1999;281:2173-2174. 2. CDC. MMWR Morb Mortal Wkly Rep. 1994;42:988-992.
20. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
How Do We Decide If a Patient May Be a
Candidate for PrEP?
Are they at substantial risk of HIV infection?
Are they able to adhere to a once-daily tablet regimen?
What is their likely tolerance of possible adverse effects?
Are they able to maintain follow-up appointments?
Are there any economic issues or other concerns?
22. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
CDC Guideline: Clinical Eligibility for PrEP
The following are required before prescribing PrEP to
identify patients for whom PrEP would be harmful or may
present risks to health:
– Documented negative HIV test result
– No signs or symptoms of acute HIV infection
– Normal renal function; no use of contraindicated medications
– Documented HBV infection status and vaccination status
CDC. PrEP Guideline. 2014.
23. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
HIV Screening
Exclude acute and chronic HIV infection[1,2]
– Consider variety of testing methods including 4th-generation
HIV Ag/Ab or HIV-1 RNA using nucleic acid–based tests
– At a minimum, document negative antibody test within the
wk before starting PrEP
– Do not accept patient-reported results
– Avoid use of oral rapid HIV testing due to lower sensitivity
1. CDC. PrEP Guideline. 2014.
2. Daar ES, et al. Curr Opin HIV AIDS. 2008;3:10-15.
24. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Acute HIV Infection
Patients who are candidates for PrEP are at substantial risk of
HIV infection
Acute HIV infection should be suspected in patients with recent
HIV exposure[1]
– Signs and symptoms include fever, rash, pharyngitis,
lymphadenopathy, myalgia, headache, diarrhea, arthralgia[2]
All PrEP candidates with a negative or indeterminate HIV
antibody test should be asked about symptoms of viral illness in
the previous month or on the day of evaluation
– Additional confirmatory testing is needed in patients reporting
recent signs or symptoms suggestive of acute HIV
1. CDC. PrEP Guideline. 2014.
2. Daar ES, et al. Curr Opin HIV AIDS. 2008;3:10-15.
25. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Documenting
HIV Status
Blue = HIV-, eligible for PrEP
CDC. PrEP Guideline. 2014.
HIV immunoassay blood test
(rapid test if available)
Retest antibody in 1 mo;
defer PrEP decision
(pending confirmatory testing)
Retest VL; defer
PrEP decision
Green = HIV status unclear;
defer PrEP decision
Negative Indeterminate Positive Consider HIV+
VL < level of detection with signs/symptoms
on day of blood draw; retest in 1 mo;
defer PrEP decision
Signs/symptoms of acute HIV
infection anytime in previous 4 wks
No Yes
Option 1 Option 2 Option 3
Send blood for HIV
antibody/antigen assay*
Positive
Negative
HIV-HIV+
HIV-VL
> 50,000 copies/mL HIV+
VL < level of detection; no signs/
symptoms on day of blood draw HIV-Orange
= HIV+, not
eligible for PrEP
VL < 50,000 copies/mL
*Use only HIV antigen antibody tests that are approved by
FDA for diagnostic purposes
Send blood for HIV-1 RNA
assay
26. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Additional Clinical and Laboratory
Evaluation
Evaluate for comorbidities that may complicate PrEP use, such
as renal disease or hepatitis, and drug interactions
– Any person with an estimated CrCl of < 60 mL/min should not be
prescribed PrEP with TDF/FTC
– Document HBV and HCV status before PrEP use; vaccinate
patients who are HBV susceptible
– Comanage HBsAg+ with a hepatologist; monitor for HBV flares
Optional assessments
– Patients with bone disease or significant risk factors for
osteoporosis should be referred for appropriate management
– Therapeutic drug monitoring
– Metabolic panel, urinalysis, STI, and pregnancy screening
CDC. PrEP Guideline. 2014.
27. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Adverse Events
Inform patients about AEs observed in HIV-uninfected
participants in PrEP trials[1]
– iPrEx: small but significant early nausea and weight loss[2]
Potential bone and renal toxicity
– Known risk associated with TDF
Potential for other serious AEs with long-term use
– However, TDF/FTC commonly used in HIV infection
Potential for drug-resistant HIV infection
– Infrequent in clinical trials but must exclude HIV infection
1. CDC. PrEP Guideline. 2014. 2. Grant RM, et al. N Engl J Med. 2010;363:2587-2599.
29. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
CDC Guideline: Recommended PrEP
Regimen
Fixed-dose TDF/FTC is the recommended PrEP regimen
for MSM, heterosexually active men and women, and IDU
who meet PrEP prescribing criteria
– Dosed as a single pill (300/200 mg) once daily
– This regimen is approved by the FDA for PrEP use
– Provide a prescription or refill for no more than 90 days
TDF alone may be considered as an alternative for IDU
and heterosexually active men and women (but not MSM)
– Based on efficacy data from clinical trials
– This regimen is NOT approved by the FDA for PrEP use
CDC. PrEP Guideline. 2014.
30. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Oral PrEP Reduces Incidence of HIV in
MSM, Even With Incomplete Adherence
iPreX OLE: open-label extension
of iPrEX trial of daily TDF/FTC
oral PrEP in MSM and
transgender women (N = 1603)
100% adherence was not
required to attain full benefit
from PrEP
– Benefit of 4-6 tablets/wk similar
to 7 tablets/wk
– 2-3 tablets/wk also associated
with significant risk reduction
Higher levels of sexual risk taking
at baseline were associated with
greater adherence to PrEP
HIV Incidence and Drug Concentrations
5
4
3
2
1
7
Tablets/
Wk
Off PrEP
On PrEP
< 2 2-3
4-6 Tablets/Wk
Tablets/
Tablets/
Wk
Wk
0
0 LLOQ 350 500 700 1000 1250 1500
TFV-DP in fmol/punch
HIV Incidence per 100
Person-Yrs
Follow-up
Risk Reduction
95% Cl
26%
44%
-31 to 77%
12%
84%
21 to 99%
21%
100%
12%
100%
86 to 100% (combined)
1. Grant R, et al. IAC 2014. Abstract TUAC0105LB. 2. Grant R, et al. Lancet Infect Dis. 2014;14:820-829.
31. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
iPrEX OLE: HIV Infection Occurred During
Gaps in PrEP Use
1.0
0.8
0.6
0.4
0.2
0
72 60 48 36 24 12 0 12 24 36 48 60
Case Control
Control
Case
Wks Preinfection Wks Postinfection
Detected in Dried Blood Spots
Control, n: 380
1306
1647
1396
1489
1441
1338
768
386 266 171 44
Case, n:
8
22
22
24
24
26
28
7
Proportion With TFV-DP
First evidence of HIV infection
TFV-DP LLOQ
TFV-DP ≥ 350 fmol/punch
1. Grant R, et al. IAC 2014. Abstract TUAC0105LB. Reprinted with permission.
2. Grant R, et al. Lancet Infect Dis. 2014;[Epub ahead of print].
32. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Key Components of Medication
Adherence Counseling
Address adverse events[1]
Identify barriers to adherence[1]
Respond to missed doses with normalization and
nonjudgement, and emphasize importance of adherence[1]
Patient self-reporting may not reflect actual adherence[2,3]
1. CDC. PrEP Guideline. 2014. 2. Van Der Straten A, et al. CROI 2014. Abstract 44. 3. Baxi SM, et al.
CROI 2014. Abstract 953.
34. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
CDC Guideline: Follow-up and Monitoring
Follow-up At Least Every 3 Mos After 3 Mos and at
CDC. PrEP Guideline. 2014.
Least Every 6 Mos
Thereafter
At Least Every
6 Mos
At Least Every
12 Mos
All patients HIV test
Medication adherence
counseling
Behavioral risk
reduction support
Adverse event
assessment
STI symptom
assessment
Assess renal
function
Test for
bacterial STIs
Evaluate need
to continue
PrEP
Women Pregnancy test
(where appropriate)
HBsAg+ HBV DNA by quantitative assay*
*Every 6-12 mos.
35. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Responding to Patient-Reported
Challenges
Discuss management of common adverse events; most
will diminish within the first few wks of treatment[1]
Patients may report feeling stigmatized by peers and
medical providers for their use of PrEP[2]
Issues related to medication access should be addressed
promptly
1. CDC. PrEP Guideline. 2014. 2. Liu A, et al. PLoS Med. 2014;11:e1001613.
36. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
iPrEx[1] Partners PrEP[2]
50
30
10
0
Placebo
TDF/FTC
0 6 12 18 24 30
Follow-up Time (Mos)
40
20
3 9 15 21 27 33
Subjects Reporting
Unprotected Sex (%)
TDF
PrEP Trials Found Decreasing Risk
Behavior Over Time
100
80
60
0
0
Placebo
48 72 96 120 144
Wks Since Randomization
Subjects Reporting Unprotected
Receptive Anal Sex (%)
40
20
24
TDF/FTC
1. Grant RM, et al. N Engl J Med. 2010;363: 2587-2599.
2. Baeten JM, et al. N Engl J Med. 2012;367:399-410.
37. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Pregnancy
PrEP use at conception and during pregnancy by the
uninfected partner may offer an additional tool to reduce
the risk of sexual HIV acquisition[1]
Data directly related to the safety of PrEP use for a
developing fetus are limited
Potential risks and limited information should be discussed
TDF and FTC are classified as FDA Pregnancy Category
B medications[2]
1. CDC. PrEP Guideline. 2014. 2. DHHS. HIV Perinatal Guideline. 2014.
38. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Stopping PrEP
Lack of guidance on when to stop PrEP in relationship to
exposures
Reasons to stop PrEP:
– Evidence of HIV infection
– Pregnancy
– Adverse events
– Chronic nonadherence
– Patient choice
If resuming PrEP after stopping, repeat standard pre-PrEP
evaluation
CDC. PrEP Guideline. 2014.
40. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Conclusions
PrEP is recommended as one prevention option for
sexually active MSM, heterosexual men and women, IDU
at substantial risk of HIV acquisition
Adherence is a key factor in PrEP efficacy
Before prescribing PrEP, acute and chronic HIV infection
must be excluded, and the patient assessed for
comorbidities that may present health risks
The recommended PrEP regimen is fixed-dose TDF/FTC
Patients prescribed PrEP should return for follow-up visits
at least every 3 mos
41. Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition
clinicaloptions.com/hiv
Resources for Healthcare Professionals
CDC PrEP Guideline: Clinical Providers’ Supplement[1]
– Patient information sheets
– Patient/provider checklist
– MSM risk index screening tool
Centers for Disease Control and Prevention[2]
– PrEP patient information sheets
1. http://www.cdc.gov/hiv/pdf/PrEPProviderSupplement2014.pdf. 2. http://www.cdc.gov/hiv/prep/.
42. Go Online for More Educational
Content on PrEP in HIV!
Interactive Virtual Presentation featuring streaming narration of these
slides and case studies illustrating PrEP decisions by expert faculty
Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA
ClinicalThought™ with expert faculty
commentaries on PrEP in HIV
clinicaloptions.com/midlevel
Notes de l'éditeur
Thank you for joining us for this important training for midlevel practitioners, “Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition: A Guidance for Midlevel Practitioners.”
My name is Kevin O’Hara. It’s a pleasure to be working with you.
And I’m Marcy Gelman, Adult Nurse Practitioner in Boston, Massachusetts.
PrEP, pre-exposure prophylaxis.
Introduction to the use of PrEP in clinical practice.
HIV in the US and worldwide continues to be a major public health crisis. There is an estimated 1.1 million Americans living with HIV, and 1 out of 6 people with HIV do not know they are infected. HIV continues to spread, leading to about 50,000 new cases of HIV each year in the US alone.
An increase in the number of individuals living with HIV reflects the success of antiviral therapy, which has turned HIV from a fatal condition into a chronic illness. However, it also means that there are more people capable of transmitting the infection to others.
IDU, injection drug user.
It’s important to consider who is at most risk for acquiring HIV. Gay, bisexual, and other men who have sex with men make up 64% of all HIV-infected people in the United States. Black and African-American men who have sex with men are at increased risk of acquiring and transmitting HIV.
Whereas heterosexual men and women and persons who inject drugs have been decreasing, the number among MSM continue to rise. As providers, we must be aware of our own risk communities when we talk about prevention and prevention methods.
PEP, postexposure prophylaxis; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
As providers we must understand the HIV prevention methods available and support our patients to understand and use the methods that best suit their lifestyles. Safer-sex counseling from healthcare providers or HIV testing counselors is critical for understanding sexual practice and risk associated negotiation and safety. Using condoms with water-based lubricant continues to remain critical and a vital tool for ongoing safety, not only for the prevention of HIV but also for other sexually transmitted infections.
Getting tested for HIV is one of the most important factors in community HIV prevention. And getting testing and treated for STIs is critical, as having an STI can increase your chance of becoming infected with HIV, and it is also an indicator for providers and patients of risk.
In addition, we must provide sterile and clean needles for injecting drug users and safe places to access and dispose of needles. Finally, we have several biomedical methods of prevention.
PrEP, pre-exposure prophylaxis.
Pre-exposure prophylaxis, or PrEP, is a strategy that involves use of antiretroviral medications to reduce the risk of HIV infection. The idea of using a well-tolerated and highly effective method of prevention has been well understood in medicine; consider prevention of malaria and antibiotics before dental procedures.
Today, PrEP is a pill taken once a day, which we will continue to talk more about in this discussion.
PEP, postexposure prophylaxis; PMTCT, prevention of mother-to-child transmission; PrEP, pre-exposure prophylaxis.
To further enhance the argument that antivirals could be highly effective in the prevention of HIV for those at risk is the success of using antivirals in prevention of mother-to-child transmission, which has essentially eradicated new infections at birth in the United States. In addition, PEP, or postexposure prophylaxis, has been used for many years in both occupational and nonoccupational exposures.
Understanding the difference between pre- and postexposure prophylaxis and educating our patients is critical for uptake and timely prevention of HIV. For a person who has one or very infrequent exposures to HIV, they could begin the use of PEP, or postexposure prophylaxis, by 72 hours of that exposure, and then take antivirals for 28 days, with the goal of preventing HIV from replicating.
For people who have repeated known exposures to HIV or engage in high-risk activity, the possibility of taking a pill prior to those exposures and continuing that throughout the course of exposure may be more effective than them taking a pill after an exposure. This is PrEP, or pre-exposure prophylaxis.
FTC, emtricitabine; IDU, injection drug user; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
The past few years, there have been major breakthroughs in biomedical research for HIV prevention. We now have data from large clinical trials to support the hypothesis that pre-exposure prophylaxis can prevent HIV.
Four large clinical trials around the globe have used tenofovir or tenofovir/FTC in MSM, serodiscordant couples, heterosexual men and women, and persons who use injection drugs. All of these trials have shown reduction in HIV incidence, with higher percent reduction in those who were taking the active study pill as opposed to the placebo.
The results of the iPrEx study resulted in the FDA approval in July 2012 of tenofovir/FTC, the first drug to be approved for HIV prevention.
FTC, emtricitabine; NR, not reported; PrEP, pre-exposure prophylaxis; TDF, tenofovir disoproxil fumarate; TFV, tenofovir.
Oral PrEP works, but adherence is critical. For IPrEx, when you analyze efficacy with the detection of tenofovir in the person’s blood, it showed that if you took tenofovir as instructed, the efficacy of PrEP was 92%.
PrEP, pre-exposure prophylaxis.
I’ve spent the last few years doing a lot of work on PrEP, in a private practice setting.
I have seen a lot of people who have read a newspaper and journal articles who have come to me for PrEP. I find many times I don’t even have to bring it up. So patient awareness has been not so much an issue for me. What have you seen?
We have noticed that patient awareness seems to be a problem. In Boston, we’re finding that the uptake is much lower than we thought it would be. In addition, what has been interesting is the lack of awareness among providers—primary care providers, various midlevel practitioners, and HIV specialists.
There has also been the situation in which primary care providers do not feel comfortable prescribing antiretrovirals, and HIV providers don’t work with HIV-uninfected individuals. So there’s been this discussion about where does PrEP best lie. In addition, I think that seeing patients every 3 months has also been a barrier for providers and for patients who are essentially healthy and want to prevent HIV.
In discussing these barriers as research researchers and clinicians, we’ve really been surprised at the slow uptake of PrEP, and it’s made us think and talk about the various barriers that we might be facing for both the users and for the providers. Potential users may not be aware of their own risk, which is really critical, or the availability of PrEP. They may not know how to access PrEP or access preventative care. They may not be able to identify a well-informed provider who understands and is willing to write a prescription. They also may not have the means to obtain or pay for these prescriptions, and they may have challenges with proper daily use as is prescribed today.
For providers, they may also not be aware of the intervention, how to bill for these visits, or they may be concerned about the complexity of the visit and the time it takes to see these patients. In addition and one of the barriers that we see frequently is providers and patients may be uncomfortable talking about the risks.
This brings us to the next part of our presentation where we discuss risk assessment and shared decision making.
In order to support our patients to make the best decision for themselves, we as providers should engage and share decision making with them. This is a collaborative process that allows patients and providers to make healthcare decisions together, take into account the best scientific evidence available, as well as the patient’s values and preferences. It’s especially useful when there is no clear best treatment option, and this is true in the case of HIV prevention. When thinking about HIV prevention, it’s important to get to know your patients, what they would like to consider to use in their toolbox to prevent HIV.
In some cases, patients will have no idea that they might be at risk, or they may be misguided by myths and lack of information. As providers, it is our job to educate, inform, and lay out the options for them so that they can best protect themselves from HIV.
CDC, Centers for Disease Control and Prevention; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
The CDC recently published PrEP guidelines, and included is a list of who is at greatest risk of acquiring HIV and may consider using daily PrEP for HIV prevention. This includes men who have sex with men and heterosexual men and women with HIV-positive sexual partners and/or high number of sexual partners; having had a recent bacterial sexually transmitted infection; inconsistent or no condom use; commercial sex workers; or living in high-prevalence areas.
In addition, they also recommend the use of PrEP for injection drug users who have HIV-positive injecting partners, who share injecting equipment, and who’ve had a recent drug treatment but are currently injecting.
This is a quote from The Hidden Epidemic, and although it was published in 1997, this sentiment is still true. It is difficult for many healthcare providers to engage in discussions about sexual behavior.
PCP, primary care providers; STI, sexually transmitted infection.
We do know that patients would like to talk to providers about sexual issues, and as midlevels we have the responsibility and the relationship with our clients to bridge this gap and make talking about sexual risk part of our practice despite what a person is coming in to talk to us about.
PrEP, pre-exposure prophylaxis.
So how do we decide if a patient may be a good candidate for PrEP? This is not an objective decision, and this should be based on ongoing discussions between you and your patients. Are they at risk? Are they able to take their medications so that they’ll be most effective? Will they have side effects that they won’t tolerate? Will they be able to get the medication and pay for it? What are their copays? These are all things we need to consider. In our patient–provider relationship, we need to have these discussions prior to and during the time in which we’re prescribing PrEP for HIV prevention.
PrEP, pre-exposure prophylaxis.
Let’s focus now on pre-PrEP counseling, testing, and appropriate clinical evaluation.
CDC, Centers for Disease Control and Prevention; HBV, hepatitis B virus; PrEP, pre-exposure prophylaxis.
The CDC provides thoughtful guidelines about clinical eligibility for PrEP. The following are required before prescribing PrEP to identify patients for whom PrEP would be harmful or may present risks to health. A documented HIV-negative test result without signs or symptoms of acute HIV infection. We also want to see normal renal function, no use of contraindicated medications, and document hepatitis B virus infection status and vaccination status.
Tenofovir/FTC has hepatitis B antiviral activity, and cessation of the antiviral medication will cause a viral rebound in patients with hepatitis B. Infrequently, especially in the setting of advanced liver disease, this may cause an acute liver failure as a result of that viral rebound and the subsequent inflammation.
Ab, antibody; Ag, antigen; PrEP, pre-exposure prophylaxis.
We want to make sure we screen properly for HIV and exclude both acute and chronic infection. Consider the variety of testing methods, including fourth-generation combination HIV antigen and antibody tests or viral load testing using nucleic acid-based tests. At a minimum, document negative antibody test within the week before starting PrEP. Do not accept patient-reported results, and avoid the use of oral rapid HIV testing due to lower sensitivity.
PrEP, pre-exposure prophylaxis.
Acute HIV infection is important to think about. Patients who are candidates for PrEP are at substantial risk for HIV infection. Acute HIV infection should be suspected in patients with recent HIV exposure or potential for exposure. Signs and symptoms include fever, rash, pharyngitis, lymphadenopathy, etc. All PrEP candidates with a negative or indeterminate HIV antibody test should be asked about symptoms of viral illness in the previous month or on the day of evaluation.
In the iPrEx trial, drug-resistant virus developed in 2 persons with unrecognized acute HIV infection at enrollment and for whom tenofovir/FTC had been dispensed. These participants had negative antibody test results before they started taking PrEP. They tested positive at a later study visit. Returning to the initial blood specimens using PCR technology during that initial visit found the virus present.
FDA, US Food and Drug Administration; PrEP, pre-exposure prophylaxis; VL, viral load.
This is a nice algorithm which shows us how we can document HIV status. As we see, we start with an HIV immunoassay blood test, and if that is positive, we would obviously move forward towards confirmatory testing.
If the person is negative or indeterminate, we continue on the algorithm. We want to look to see if any signs or symptoms of acute infection are present. I would additionally say we want to ascertain what their risk is for infection as well. And if either are present, we would continue down the algorithm with one of 3 options.
The first is to delay PrEP and repeat antibody screening in 1month. Option 2 is to send that blood specimen for our fourth-generation antibody/antigen combination test. And option 3 is to send the blood for HIV-1 viral load study. The time difference between option 2 and 3 is real but minimal, as option 2 with its p24 antigen study will identify HIV infections generally within about 2 weeks and is a very sensitive study.
CrCl, creatinine clearance; FTC, emtricitabine; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection; TDF, tenofovir.
We want to consider other tests beyond infection screening in patients that are considering PrEP. We want to evaluate for comorbidities that may complicate PrEP use, such as renal disease, viral hepatitis, and drug interactions. Any person with an estimated creatinine clearance of less than 60 should not be prescribed PrEP with tenofovir/FTC. Document hepatitis B and hepatitis C status before PrEP use, and vaccinate patients who are hepatitis B susceptible. And those patients who live with hepatitis B, we want to consider managing them properly with a hepatologist—someone who can help us monitor for hepatitis B flares and properly assess the patient if that were to occur.
There are optional assessments. Patients with bone disease or significant risk factors for osteoporosis should be referred for appropriate management. Therapeutic drug monitoring in certain settings is an option to help evaluate adherence and absorption. And we may also consider a metabolic panel, urinalysis, STI, and pregnancy screenings, when appropriate.
AE, adverse event; FTC, emtricitabine; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
We must encourage our patients to think about the risk and benefit of PrEP because that conversation is likely going to evolve as their risks change and their health changes. We want to inform patients about adverse events observed in HIV-uninfected participants in PrEP trials.
Fortunately, these adverse events have been mild and not frequently reported. In the iPrEx trial, for example, there was a small but statistically significant side effect of early nausea which likely led to some small weight loss. As we know, tenofovir is associated with bone and renal toxicity, and there is the potential for other serious adverse effects with long-term use.
When counseling my patients, I often tell them about my experience with HIV therapy. I reassure them that tenofovir and FTC has been prescribed for many years in people living with HIV, and we have a lot of confidence in our knowledge of the medication. But I do explain that there are some areas where understanding is lacking. For example, I’ll say that men and women living with HIV often have many chronic health problems, and while HIV is likely the cause for that, we’re uncertain how much medications such as tenofovir and FTC contribute to that. So there is some acceptance on the part of the patient as to the potential for other adverse effects, especially with long-term use, and as was shown earlier, the potential for drug-resistant HIV infection if somebody had unrecognized acute HIV infection when they started taking PrEP.
Adherence counseling.
CDC, Centers for Disease Control and Prevention; FDA, US Food and Drug Administration; FTC, emtricitabine; IDU, injection drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
Fixed-dose tenofovir/FTC is the recommended PrEP regimen for men who have sex with men, heterosexually active men and women, and intravenous drug users who meet PrEP prescribing criteria. It is dosed as a single pill taken once daily. This regimen is approved by the FDA for PrEP use. Provide a prescription or refill for no more than 90 days to ensure follow-up and contact with the patient.
Tenofovir alone may be considered as an alternative for intravenous drug users and heterosexually active men and women, but not the MSM community at this point, based on efficacy data from clinical trials. This regimen, by the way—tenofovir alone is not approved by the FDA for PrEP use.
FTC, emtricitabine; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TDF, tenofovir; TFV-DP, tenofovir diphosphate.
In the iPrEx open-label extension study of tenofovir/FTC in men who have sex with men and transgender women, we found that 100% adherence was not required to attain full benefit from PrEP. The benefit of 4-6 tablets a week was similar to 7 tablets a week, and 2-3 tablets a week was also associated with a significant risk reduction, although not as strong. We also found that higher levels of sexual risk taking at baseline were associated with greater adherence to PrEP.
LLOQ, lower limit of quantification; PrEP, pre-exposure prophylaxis; TFV-DP, tenofovir diphosphate.
This slide further identifies the importance of adherence in the iPrEx open-label study. Here we look at 2 participants who became infected with HIV and that were matched with similar controls by site of study, age, etc. And this demonstrates HIV infection emerges in this setting of reduced drug levels, and these drug levels were obtained through dried blood spot evaluation of tenofovir.
Key components of medication adherence counseling include addressing adverse effects. So if somebody’s having persistent nausea, altered bowel movements, we want to try and identify ways in which we can reduce that adverse effect burden. We want to identify barriers to adherence, which may include shift work issues such as our case or logistical issues—getting to the pharmacy—financial issues with copayments, etc.
Respond to missed doses with normalization, nonjudgment, and emphasize the importance of adherence. Keep in mind, patient self-reporting of adherence may not reflect actual adherence. We can use other methods for this, although many are not available in the clinical realm, and that includes therapeutic drug monitoring, and also pharmacy reporting of prescription refills.
Let’s move forward with on-treatment follow-up
CDC, Centers for Disease Control and Prevention; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
Patients should be returning for follow-up at least every 3 months. Consider a visit initially after 1 month to assess HIV status, adverse effects, or patient concerns. With all patients, at least every 3 months we want to screen for HIV, offer medication adherence counseling, and behavioral risk reduction support. We want to evaluate for side effects and also sexually transmitted infection symptoms, especially those of HIV.
After 3 months and at least every 6 months thereafter, assess renal function. At least every 6 months, test for bacterial sexually transmitted infections, and at least every 12 months, evaluate the need to continue PrEP.
With women, we want to test for pregnancy when appropriate. And in those patients living with hepatitis B, every 6-12 months, we want to be doing an HBV DNA quantitative assay. And in the event of viral rebound, we want to make sure we are evaluating the health of the liver and patient status properly.
My first visit with a patient when we are about to start PrEP includes not only an agreement that the patient accept the potential adverse effects and adherence but also agrees to follow-up on PrEP; I really identify it as a significant commitment on their part. And I identify myself as an ally to support them through this as much as possible, but really for that person’s own health, 3 months is very important for follow-up.
PrEP, pre-exposure prophylaxis.
Let’s talk about responding to patient-reported challenges. First, we want to discuss the management of common adverse events with patients even before they start PrEP and really emphasize that most will diminish within the first few weeks of starting treatment. We often refer to this as the start-up syndrome. And if there’s nausea, we may encourage patients to take the medicine with food and/or before going to bed at night. And there are also medications which can sometimes be prescribed if the nausea is particularly burdensome.
Patients may report feeling stigmatized by peers and medical providers for their use of PrEP, and I’ve heard this from a number of patients utilizing these medications. And I think it’s important that we empower patients to identify a healthcare team which is affirming towards their particular situation. And I think in patients who are identifying stigma from peers, I think we should in a way congratulate our patients for taking ownership of their health and being comfortable discussing this issue. As we identified before, there’s certainly a lack of awareness among the community about PrEP.
Issues related to medication access should be addressed promptly, and this may include financial, logistical reasons. As a clinician, I don’t always have the answer to this, but I can at least be empathetic and try and direct someone to a pharmacist or a pharmaceutical company payment assistance program that can be of greater assistance.
FTC, emtricitabine; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
PrEP trials have found decreasing risk behavior over time. This counters what many thought would occur, a phenomenon known as risk compensation. So taking PrEP reduces risk towards HIV, and as a result, individuals may increase risky behavior, whether it be through unprotected sex or numbers of sexual partners.
These 2 graphs suggest reduced risky behavior in 2 randomized clinical trials. The iPrEx and Partners PrEP trial showed decreased unprotected sex. However, these trials were placebo controlled, so the participants may have been uncertain if they were taking an active agent or not. Additionally, these randomized clinical trials came with a significant amount of behavioral counseling and education which may not be available in a real-world setting.
FDA, US Food and Drug Administration; FTC, emtricitabine; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
PrEP use at conception and during pregnancies by the uninfected partner may offer an additional tool to reduce the risk of sexual HIV acquisition. Data directly related to the safety of PrEP use for a developing fetus are limited. Potential risks and limited information should be discussed. Tenofovir and FTC are classified as FDA Pregnancy Category B medications.
In the PrEP trials with heterosexual women, these medications were promptly discontinued for those who became pregnant, so the safety for exposed fetuses could not be adequately assessed. A single small study of periconception use of tenofovir in 46 uninfected women in HIV-discordant couples found no ill effect on the pregnancy and no HIV infections. Additionally, tenofovir and FTC are widely used for the treatment of HIV infection and continued during pregnancies that occur, the data on pregnancy outcomes in the Antiretroviral Pregnancy Registry provide no evidence of adverse effect among fetuses exposed to these medications.
PrEP, pre-exposure prophylaxis.
There is a lack of guidance on when to stop PrEP in relationship to an exposure. There are a number of reasons to stop PrEP: Evidence of HIV infection is one of them; pregnancy; adverse effects, including renal failure; chronic nonadherence should definitely be an issue brought up with our patients, especially since they may not be receiving much benefit at all if the adherence is below the thresholds previously discussed; and patient choice to stop. If resuming PrEP after stopping, repeat the standard pre-PrEP evaluation.
FTC, emtricitabine; IDU, injection drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TDF, tenofovir.
In conclusion, PrEP is recommended as one prevention option for sexually active men who have sex with men, heterosexual men and women, and injection drug users who are at substantial risk of HIV acquisition. Adherence to PrEP is a key factor in the efficacy of this method. Before, as providers, we begin to prescribe PrEP, we want to assess for acute and chronic HIV infection, and we must exclude these. We also want to assess our patients for comorbidities that may be present as health risks for them using these medications to prevent HIV. The recommended PrEP regimen is fixed-dose tenofovir/FTC, and patients prescribed PrEP should return for follow-up visits at least every 3 months.
CDC, Centers for Disease Control and Prevention; PrEP, pre-exposure prophylaxis.
We’ve included some resources for healthcare professionals to use as you begin or consider using PrEP in your practice to support your patients to prevent HIV.